SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Booker T. Washington

PatientBooker T. Washington
Date of birth1967-04-05
IdentifiersMRN HR-NI017-SYN; SSN (made up) 000-17-2284
Document date2026-05-11
AuthorLorraine Whitfield, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

One-week blood pressure and kidney safety check. [S]

History of Present Illness

Mr. Washington returns one week after starting amlodipine and losartan for severe hypertension with stage G3b chronic kidney disease. His home readings, taken twice daily, have fallen from above 200 systolic to the 160s and 170s over 100s. He has had one mild frontal headache this week, fewer than before, and no chest pain, breathlessness, weakness, confusion, or sudden change in vision. His palpitations are less frequent. He has had no lightheadedness on standing and no ankle swelling, and he takes both medicines every morning. His reading vision is still blurred and he still gets up twice a night to urinate. He asks how to keep to the plan on travel days. His nephrology consultation, kidney ultrasound, and echocardiogram were done today. [S]

ElementDetail
Home blood pressure160s to 170s over 100s, down from above 200 systolic
SymptomsOne mild headache this week; palpitations less frequent
Warning signsNo chest pain, breathlessness, weakness, confusion, or sudden vision change
Medication toleranceNo lightheadedness or ankle swelling
AdherenceEvery dose taken
Patient goalA plan that works on travel days

Review of Systems

SystemResultFinding
ConstitutionalPositiveTires by midafternoon; weight stable
EyesPositiveReading vision blurred, unchanged; no sudden loss of vision
CardiovascularPositiveOccasional palpitations, less frequent; no chest pain or ankle swelling
RespiratoryNegativeNo breathlessness
GenitourinaryPositiveUp twice a night to urinate; no dysuria or blood in the urine
NeurologicalPositiveOne mild frontal headache; no weakness, numbness, confusion, or lightheadedness on standing

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Amlodipine 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-05-04activeS
Losartan 50 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-05-04 to 2026-05-11completedS
Losartan 100 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-05-11activeS
Dapagliflozin 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-05-11activeS
Atorvastatin 20 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-05-04activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-05-11Body height170cmS
2026-05-11Body weight71kgS
2026-05-11Body mass index (BMI) [Ratio]24.6kg/m2S
2026-05-11Systolic blood pressure172mm[Hg]S
2026-05-11Diastolic blood pressure104mm[Hg]S
2026-05-11Heart rate82/minS
2026-05-11Respiratory rate16/minS
2026-05-11Body temperature36.7CelS
2026-05-11Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-05-11Sodium [Moles/volume] in Serum or Plasma138mmol/L135-145 mmol/LNormalS
2026-05-11Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
2026-05-11Carbon dioxide, total [Moles/volume] in Serum or Plasma22mmol/L22-29 mmol/LNormalS
2026-05-11Urea nitrogen [Mass/volume] in Serum or Plasma36mg/dL6-24 mg/dLHighS
2026-05-11Creatinine [Mass/volume] in Serum or Plasma2.2mg/dL0.74-1.35 mg/dLHighS
2026-05-11Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M34mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
2026-05-11Glucose [Mass/volume] in Serum or Plasma95mg/dL70-99 mg/dLNormalS
2026-05-11Left ventricular Ejection fraction60%50-70%NormalS

Physical Exam

Vital signs recorded on 2026-05-11; see the Vital Signs section. [S]

SystemFinding
GeneralAlert, articulate, and in no distress
Blood pressure172/104 mmHg, the average of two seated readings after five minutes' rest with a validated cuff
EyesUndilated fundi show the arteriolar narrowing seen last week; no hemorrhages or papilledema
HeartRegular rhythm, rate 82; S4; no murmur
LungsClear
ExtremitiesNo edema
NeurologicalFluent speech; no focal deficit

Problems

ProblemClinical statusVerificationCodeProvenance
Severe hypertension with hypertensive kidney disease; synthetic modern diagnosis linked to the documented 1915 blood pressure of 220/150activeconfirmed I12.9S — Synthetic active diagnosis for the teaching episode; the 1915 findings remain D and the retrospective diagnosis remains R.
Chronic kidney disease stage G3b A3 (severely increased albuminuria), attributed to hypertensive nephrosclerosisactiveconfirmed N18.32S — Synthetic diagnosis supported by small echogenic kidneys and albuminuria; linked to the documented 1915 diagnosis of Bright's disease.
Hypertensive retinopathy, both eyes, without papilledemaactiveconfirmed H35.033S — Synthetic funduscopic finding that echoes the documented failing vision.
Mild anemia of chronic kidney disease, iron replete; monitoractiveconfirmed D63.1S — Synthetic finding from the baseline hemoglobin and iron studies.
Hyperlipidemiaactiveconfirmed E78.5S — Synthetic finding from the baseline LDL cholesterol.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryPotassium and creatinine (basic metabolic panel)2 to 4 weeks after starting or titrating losartan, dapagliflozin, or a diuretic; with each eGFR drawCompleted todayOne week after starting losartan, earlier than the CMID window because of severe hypertension and eGFR 36; the care plan uses one to four weeks. Potassium 4.6, creatinine 2.2 mg/dL (up 5 percent), eGFR 34, bicarbonate 22
LaboratoryPotassium and creatinine after today's changes2 to 4 weeks after titrating losartan or starting dapagliflozinDueLosartan doubles and dapagliflozin starts today; drawn at the three-week check
LaboratoryeGFR and urine albumin-creatinine ratioAbout 3 times a year for G3b A3Up to dateUrine albumin-creatinine ratio 820 mg/g at diagnosis; repeat once the regimen is complete
LaboratoryCalcium, phosphate, and PTHEvery 6 to 12 months in G3bUp to dateCalcium 9.1, phosphate 4.2, PTH 92 pg/mL (mildly raised) at diagnosis; next at the six-month review
Laboratory25-hydroxyvitamin DOnce at baselineDueNot drawn at diagnosis; PTH is mildly raised. To be drawn with the six-month calcium, phosphate, and PTH
LaboratoryUrinalysis with microscopyAt diagnosis, then with a change in statusDeferredNot on file from the diagnostic workup, a deviation from the protocol. It screens for blood or casts that would point away from hypertensive nephrosclerosis. Today's ultrasound and the history fit hypertensive kidney disease, so no harm is evident. Corrective action: obtain it if albuminuria does not fall on treatment or kidney function changes unexpectedly
LaboratoryHemoglobinAt least yearly in G3Up to date12.6 g/dL at diagnosis; iron studies show iron-replete anemia of chronic kidney disease
SurveyKidney failure risk equation, 2 and 5 yearsYearly in G3 to G5; before referral decisionsDeferredNot calculated before the nephrology referral, a deviation from the protocol. The referral stood on other criteria (eGFR below 60 with severely increased albuminuria), so no harm resulted. Corrective action: calculate at the six-month review, once eGFR has settled on full therapy
ReferralNephrology consultationeGFR below 60 with persistent A3 albuminuriaCompleted todaySeen today; agrees with the plan
ImagingKidney ultrasoundAt diagnosis when chronicity or obstruction is in question; not for routine surveillanceCompleted todayKidneys 9.4 and 9.6 cm and echogenic, without hydronephrosis: chronic kidney disease, not obstruction
ImagingTransthoracic echocardiogramAt diagnosis for stage 2 hypertension or suspected left ventricular hypertrophyCompleted todayConcentric left ventricular hypertrophy; ejection fraction 60 percent
Imaging12-lead ECGAt diagnosisUp to dateSinus rhythm with left ventricular hypertrophy by voltage last week
ExaminationFunduscopic examinationYearly in chronic hypertensionUp to dateDilated examination last week; next in a year
ExaminationStandardized office blood pressureEvery visit; target systolic below 120 when toleratedCompleted today172/104 mmHg
ExaminationWeight, BMI, and cardiac auscultationEvery visitCompleted today71 kg, BMI 24.6; S4 without murmur
LaboratoryHbA1c and TSHHbA1c yearly; TSH at diagnosisUp to dateHbA1c 5.4 percent and TSH 1.8 at diagnosis
SurveyPHQ-9Yearly in hypertensionUp to dateScore 4 at diagnosis
Medication safetyMedication review: NSAID avoidance and kidney dosingEvery visitCompleted todayNo NSAIDs or over-the-counter products; doses checked for eGFR 34
Medication safetyVaccination reviewYearly in chronic kidney diseaseCompleted todayPCV20 and hepatitis B vaccine dose 1 given today; influenza vaccine given last fall
Self-managementHome blood pressure log, sodium below 2 g a day, and activityEvery visitCompleted todayHome log reviewed; travel plan agreed

Goal progress:

Immunizations given today: Pneumococcal conjugate vaccine PCV20; Hepatitis B vaccine (HepB-CpG), dose 1 of 2 [S]

Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); CMID: Clinical Monitoring Intelligence Database, hypertension and chronic kidney disease monographs (2026)

Follow-up: Three-week check with potassium and creatinine after the losartan increase and dapagliflozin start. Next scheduled visit 2026-06-01: three-week check after losartan titration and dapagliflozin start. [S]